BillionToOne (BLLN) Stock Price

BillionToOne Price

NYSE·CLOSED
98.36
​
Market closed

Revenue has compounded at 106.2% per year over the past 2 years to 305.11 M USD. BillionToOne's net margin stands at 2.4%, up from -115.3% several years earlier. Analysts set a median price target of 127.50 USD, implying 29.6% above the current price. Of 14 analysts, 11 rate the stock a buy — an overall Buy consensus.

BillionToOne stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BillionToOne business model & stock analysis

BillionToOne Inc, a US-based company headquartered in Menlo Park, California, operates within the Health Care sector. The company is scheduled to go public on November 6, 2025, with the ticker symbol BLLN and ISIN US0901681058. BillionToOne Inc is described as a precision diagnostics company focused on innovative molecular counter technology. The company's Quantitative Counting Template (QCT) platform is noted for its ability to count DNA molecules at the single-count level, enabling the detection of risks associated with common and severe genetic diseases. The company's product UNITY is a noninvasive prenatal screening test that analyzes fetal cell-free DNA in a maternal blood sample to screen for cystic fibrosis (CF) and spinal muscular atrophy (SMA). The product is designed to provide diagnostic insights without invasive procedures, leveraging the QCT platform's unique counting capabilities. The company's website is https://www.billiontoone.com/. As of the provided information, no additional details about the company's founding year, key personnel, acquisitions, or specific financial figures are available. The company's focus remains on advancing precision diagnostics through its proprietary technology, targeting genetic disease risk assessment in prenatal care.

Frequently asked questions about BillionToOne

Analysts currently set an average price target of 127.50 USD for the BillionToOne stock (median: 127.50 USD), implying +27.0 % versus the latest price. The consensus is based on 14 analyst ratings.

14 analysts currently rate the BillionToOne stock: 11 recommend buying, 3 holding and 0 selling. For 2026, analysts expect BillionToOne to generate revenue of 454.78 M USD and earnings per share of 0.78 USD.

Converted at the current exchange rate, the BillionToOne share trades at 87.62 EUR (98.36 USD).

The expected revenue of BillionToOne is 454.78 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of BillionToOne is 35.51 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of BillionToOne is currently 126.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BillionToOne stock.

The price-to-sales ratio (P/S) of BillionToOne is currently 9.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BillionToOne stock.

The Eulerpool Quality Score for BillionToOne is 3/10.

The ISIN of BillionToOne is US0901681058. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of BillionToOne is BLLN. The ticker symbol is used to trade BillionToOne shares on the stock exchange.

Fair ValueTerminal
93.44 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 6, 2025
ISIN
US0901681058
Cusip
090168105
Market capitalization
4.50 B USDMid Cap
52-Week Range
PEG
20.30
P/E ratio
P/Ee 2026
126.79
P/Ee 2027
97.97
P/Ee 2028
56.72
P/Ee 2029
35.55
P/Ee 2030
34.45
P/Se
9.91
EV/EBIT
253.93
P/B Ratio
9.38
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1.37 %
Last updated Oct 19, 2026, 5:00 PM

BillionToOne Peer Group

All fundamentals and in-depth analysis of BillionToOne

Our stock analysis for BillionToOne stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BillionToOne. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.